2021, Alpha and Beta - Business Valuation Zone

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2021

Alpha

Beta

Learning Old Lessons From Recent Life Sciences Earnout Disputes: Above All Else, Words Matter

Cooley M&A

OCTOBER 24, 2024

According to SRS Acquiom’s 2023 Life Sciences M&A Study , 91% of private bio/pharma deals, 59% of private medical device deals, and 47% of private diagnostics and research technologies deals in the study included an earnout between 2021 and 2023. Comparatively, just 21% of non-life sciences deals included an earnout in the same period.

Beta

Beta Alpha Marketability Technology

Data Update 1 for 2024: The data speaks, but what does it say?

Musings on Markets

JANUARY 5, 2024

Beta & Risk 1. Market alpha Many of these corporate finance variables, such as the costs of equity and capital, debt ratios and accounting returns also find their way into my valuations, but I add a few variables that are more attuned to my valuation and pricing data needs as well. Return on Equity 1. Debt Details 1. Buybacks 2.

Dividends

Dividends Risk Premium Equity Book Value

Learning Old Lessons From Recent Life Sciences Earnout Disputes: Above All Else, Words Matter

Data Update 1 for 2024: The data speaks, but what does it say?

Stay Connected